Children under six can benefit Taking jobs to lose weightResearchers suggest.
About a third of children are leaving Primary school 11 old weighs of age or living together obesityAccording to data by the Department of Health and Social Care, put them at risk diabetesStroke and some cancer later in life.
While a number Weight loss jabs Available on NHS in England – either to manage weight or help treat type 2 diabetes – they are It is recommended only for adultsIn the US, weight loss jab wagovi is approved for children aged 12 to 17 with obesity.
An American study published in Jama pediatrics Weight -losing jabs such as Vejovi and Maunzaro can help children under six with obesity and type 2 diabetes.
However, researchers found that stomach problems were “quite normal” among the youth taking drugs.
About 1.5 million people in the UK take medicines like Mounaro, Ozmpic and Vagovi to deal with conditions such as obesity and diabetes.
Drugs known as GLP-1 agonist mainly treat diabetes, but are also available through NHS or private providers to help adults with high body mass index.
Drugs are used mainly to control blood sugar levels, but they also reduce food deficiency and, as a result, can cause rapid weight loss.
Experts from America performed a review and meta -analysis of 18 tests involving GLP -1 agonist in youth between the ages of six and 17 years.
Overall, studies consisted of 1,402 children and the effectiveness of GLP -1 agonists was compared to placebo remedies in young people who were thick, overweight, pre -diabetes or type 2 diabetes.
Researchers “improved” blood sugar control and weight 2 diabetes in drugs with blood sugar control and weight 2 diabetes.
However, he stated that “gastrointestinal adverse events”, which could include nausea, vomiting, diarrhea and constipation, were “quite normal” among drugs.
Writing in the journal, researchers stated that future tests and long -term follow -up in more real -world studies are “necessary to establish the long -term effects of GLP -1 drugs in children and adolescents”.
The latest data published by NHS suggests that 22.1 percent of children in England in 6 (10 to 11 years of age) were below 22.7 percent in 2022-2023 in 2023-2024.
Despite falling for the third consecutive year, the figure is still higher than the years before the epidemic.
Somewhere else, the government’s National Child Measurement Program found that one of the 10 children attending primary school in England had more than 9.2 percent in 2023-2024 in 2022-2023.
Professor Neveda Sattar, Professor of Cardiometabolic Medicine at Glasgow University, said: “We need more security assessment for new drugs including development and puberty and to consider how long such drugs are required. It should be noted that we can not solve childhood obesity by drugs alone.